Study of Antidepressants in Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Parkinson DiseaseDepression
Interventions
DRUG

paroxetine

Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.

DRUG

venlafaxine

Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.

OTHER

placebo

an inactive substance

Trial Locations (18)

14627

University of Rochester, Rochester

21218

Johns Hopkins University, Baltimore

21250

University of Maryland, Baltimore

22901

University of Virginia, Charlottesville

30322

Emory University School of Medicine, Atlanta

32610

University of Florida, Gainesville

33136

University of Miami, Miami

38163

University of Tennessee-Memphis, Memphis

40536

University of Kentucky, Lexington

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston

94143

University of California San Francisco, San Francisco

97239

Oregon Health Sciences University, Portland

02215

Beth Israel Deaconess Medical Center, Dept. of Neurology E/KS 430, 330 Brookline Avenue, Boston

Unknown

Medical University of Ohio, Toledo

N6A 5A5

London Health Sciences Centre, University Campus Room A10-325, 339 Windermere Road, London

H2W 1T8

Hotel-Dieu Hospital-CHUM, Montreal

00936

University of Puerto Rico, San Juan

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Rochester

OTHER

NCT00086190 - Study of Antidepressants in Parkinson's Disease | Biotech Hunter | Biotech Hunter